The irony cannot be missed: A Rose Garden event to announce the nomination of a Supreme Court justice widely expected to tilt the court toward limiting access to abortion became a super-spreader event for coronavirus, which infected many of the dignitaries gathered there. And the miracle cure touted by the president himself was made possible in some way by the scientific use of aborted fetal tissue.
Since the announcement that President Donald Trump was treated with an experimental cocktail of drugs that he said has made him feel better than he has in 20 years, attention has increasingly focused on how one of those treatments a cocktail of antibodies manufactured by Regeneron was developed and tested. And the same may be true for the other drug used on Trump and other coronavirus patients, Remdesivir.
Two ironic facts have risen to the surface and have been confirmed by multiple sources, however: (1) The new molecular treatment was developed and/or tested in some way involving cells originally derived from an aborted fetus; and (2) the very kind of research that made this therapy possible was shut down by the Trump administration within the past year.
The very kind of research that made this therapy possible was shut down by the Trump administration within the past year.
Critics cite these facts as evidence of hypocrisy by abortion opponents who for years have lambasted stem cell research as barbaric and immoral but now are willing to laud a miracle drug made possible by that very research.
On the other hand, some pro-life advocates dispute the actual use of aborted cells in the research or claim the original cells were obtained so long ago that there is no moral jeopardy in the modern drug.
One Dallas-based medical ethicist noted privately: I understand that many vaccines in the past included a cell line derived from the lung tissue of aborted fetuses, but I have also read that the cell line is either so attenuated or even absent that even the Catholic Church has withdrawn its objections.
And therein lies the nuance of this situation.
Amid these competing claims and an effort by Regeneron to carefully thread the needle of disclosure the MIT Technology Review published an article Oct. 7 by Antonio Regalado that minced no words:
This week, President Donald Trump extolled the cutting-edge coronavirus treatments he received as miracles coming down from God. If thats true, then God employs cell lines derived from human fetal tissue.
The MIT article continues to explain that the antibody treatment Trump received was developed with the use of a cell line originally derived from abortion tissue, according to Regeneron Pharmaceuticals, the company that developed the experimental drug.
And heres where things get quite technical.
According to the MIT journal and other published sources, the molecules in the treatment Trump received are manufactured in cells from a hamsters ovary not in human cells. However, cells originally derived from a fetus were used in another way. According to Regeneron, laboratory tests used to assess the potency of its antibodies employed a standardized supply of cells , whose origin was kidney tissue from an abortion in the Netherlands in the 1970s.
These cells have been immortalized, which means they have been reproduced, divided and shared many times through the years, so that the line of cells used today is, in a way, a descendant of the original cells obtained from the aborted kidney tissue.
Because the cells were acquired so long ago, and have lived so long in the laboratory, they are no longer thought of as involving abortion politics.
Thus the MIT journal concludes: The two antibodies Regeneron eventually put forward as an experimental treatment, which may have saved Trumps life, would have been selected using exactly such tests. Because the cells were acquired so long ago, and have lived so long in the laboratory, they are no longer thought of as involving abortion politics.
In June 2019, the Trump administration blocked federal funding for new scientific research using fetal tissue derived from abortions.
Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trumps administration, the Department of Health and Human Services said in a statement.
And then this important line: Intramural research that requires new acquisition of fetal tissue from elective abortions will not be conducted.
The Trump administration policy hailed widely as a victory for the anti-abortion cause restricted new acquisition of fetal tissue.
The New York Times quoted an administration official who said the presidents acceptance of this coronavirus treatment should not be seen as a contradiction. The administrations policy on fetal tissue research specifically excluded cell lines made before June 2019, said the official, who did not wish to be identified because he was not authorized to speak about the matter. Scientific products made using cell lines that existed before then would not implicate the administrations policy on the use of human fetal tissue from elective abortions, the official said.
The fact that most anti-abortion advocates have remained silent about this apparent contradiction also was addressed by the MIT journal: Most likely, their hypocrisy was unwitting. Many types of medical and vaccine research employ supplies of cells originally acquired from abortion tissue. It would have taken an expert to realize that was the case with Trumps treatment.
In June 2019, the journal Nature reported on the Trump administrations ban on fetal-tissue research that receives federal funding, especially through the National Institutes of Health.
Scientists employ fetal tissue to explore topics as diverse as infectious disease, human development and disorders of the eye.
The administration said it will set up an ethics-review board to evaluate each NIH grant application that would support research with fetal tissue, which is collected from elective abortions. But the government has already decided against renewing its contract with a laboratory at the University of California, San Francisco, that uses fetal tissue to study HIV, Nature reported. The announcement comes after a sustained push by abortion opponents to limit scientific research with fetal tissue despite warnings from researchers that using the tissue is the only way to study some health problems. Scientists employ fetal tissue to explore topics as diverse as infectious disease, human development and disorders of the eye.
The journal quoted UCSF chancellor Sam Hawgood saying this government decision was politically motivated, shortsighted and not based on sound science. Todays action ends a 30-year partnership with the NIH to use specially designed models that could be developed only through the use of fetal tissue to find a cure for HIV.
The New York Times reported that the ethics board set up to review proposed uses of fetal stem cells in research met for the first time in July and in August, the board rejected 13 of the 14 proposals it reviewed; the approved proposal relied on tissue that had already been acquired.
The ethical debate over this kind of research is not going away and, in fact, could escalate as work continues on COVID-19 vaccines.
The New York Times quoted David Prentice, vice president of the Charlotte Lozier Institute, who wrote in September: One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the development, production or testing.
Prentices own analysis found 13 vaccine candidates that rely in some way on fetal cell lines.
In response, the Times quoted James Sherley, a research scholar at the Charlotte Lozier Institute and director of the adult stem cell company Asymmetrex, who said this kind of research is not morally responsible. There are alternatives there are lots of ways that dont require the death of anyone.
Additional reporting on this issue has been published in Science magazine and Input magazine.
Related articles:
Is this election all about abortion? It depends on who you ask
Read the original:
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments